| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | Rakuten Medical | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $874.92M | Series F-3 | 1/7/2026 | $3.6M | $636.9M | $1.03 | Taiwania Capital, Axil Capital Group, Daiwa Securities, Mitsui Sumitomo Insurance Company, Sumitomo Mitsui Banking, ABIES Capital, Nexus CVC, OEP Group, SBI Group, Rakuten, Mickey Mikitani | ||||
 | Tessera Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $100.00K | -- | 1 | -- | Not available | -- | -- | $587.85M | Series D | 12/1/2025 | $200M | $668.33M | $5.18 | Bill & Melinda Gates Foundation, Regeneron | ||||
 | Loyal | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $236.56M | Series C | 2/11/2026 | $95.46M | $614.38M | $12.26 | Age 1, Baillie Gifford | ||||
 | ADARx Pharmaceuticals | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $352.5M | Series C | 8/9/2023 | $200M | $848.26M | $9.75 | Bain Capital Life Sciences, TCGX, Blackrock, Commodore Capital, Cormorant Asset Management, HBM Healthcare Investments, Invus, Marshall Wace, Redmile Group, T. Rowe Price Associates, Venrock Healthcare Capital Partners, Vivo Capital, Ascenta Capital, Lilly Asia Ventures, OrbiMed Advisors, SR One Capital Management | ||||
 | Odyssey Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $413.6M | Series D | 9/10/2025 | $213.63M | $527.3M | $14.62 | Affinity Asset Advisors, Dimension Capital, Jeito Capital, Lightspeed Ventures, TPG, Wedbush Healthcare Partners | ||||
 | Nusano | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $474.68M | Series D-1 | 4/21/2026 | $180M | $655.01M | $1.25 | Undisclosed Investors | ||||
 | Saliogen Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $156.22M | Series B | 1/5/2022 | $132.25M | $549.61M | $105.86 | GordonMD Global Investments, EPIQ Capital Group, Fidelity, T. Rowe Price, D1 Capital Partners, SymBiosis, Cystic Fibrosis Foundation, RD Fund | ||||
 | Terray Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $326.97M | Series C | 9/9/2026 | $125M | $722.36M | $10.28 | Undisclosed Investors | ||||
 | Shoreline Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $186M | Series B | 11/2/2021 | $140M | $527.99M | $10.07 | Ally Bridge Group, Eventide Asset Management, BeiGene, Irving Investors, Kingdon, NS Investment, Piper Heartland Healthcare Capital, Superstring, BVF Partners, Commodore Capital, Cormorant Asset Management, Janus Henderson Investors, Kite, Stork Capital, Wedbush Healthcare Partners | ||||
 | Embark | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $94.55M | Series B | 7/26/2021 | $75M | $759.47M | $16.96 | SoftBank, F-Prime Capital, SV Angel, Slow Ventures, Freestyle Capital, Third Kind Venture Capital | ||||
 | Sionna Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $331.32M | Series C | 3/6/2024 | $181.86M | $523.7M | $9.76 | Enavate Sciences, Viking Global Investors, Perceptive Advisors, RA Capital, TPG, Atlas Venture, Cystic Fibrosis Foundation, T. Rowe Price, Qatar Investment Authority, OrbiMed | ||||
 | Parabilis Medicines | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $811.88M | Series F | 1/8/2026 | $305.25M | $681.2M | $6.16 | RA Capital Management, Fidelity, Janus Henderson Investors, Frazier Life Sciences, Soleus Capital, venBio Partners, Cormorant Asset Management, Nextech Invest, ARCH Venture Partners, Milky Way Investments, GV, T. Rowe Price, Marshall Wace, General Catalyst, Invus, Farallon Capital Management, Foresite Capital, Rock Springs Capital, HBM Healthcare Investments, Samsara BioCapital, Catalio Capital Management, Sixty Degree Capital, Alderline Group | ||||
 | Paradigm Health | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $281M | Series B-1 | 12/4/2025 | $57.73M | $505.1M | $1.00 | ARCH Venture Partners, DFJ Growth, F-Prime Capital, General Catalyst, GV, Lux Capital, Mubadala Capital, BrightEdge | ||||
 | ReCode Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $397.77M | Series B | 9/23/2025 | $290M | $588.16M | $9.23 | Matrix Capital Management, Pfizer Ventures, EcoR1 Capital, Sanofi Ventures, Tekla Capital Management, Superstring Capital, NS Investment, OrbiMed, Vida Ventures, MPM Capital, Colt Ventures, Hunt Technology Ventures, Osage University Partners, Bayer, Amgen, CF Foundation | ||||
 | Scorpion Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $1.02B | Series C-2 | 7/16/2024 | $24.31M | $821.83M | $2.54 | Frazier Life Sciences, Lightspeed Venture Partners, Willett Advisors, Omega Funds, Vida Ventures, Atlas Venture, Abingworth, Fidelity, Boxer Capital, EcoR1 Capital, Surveyor Capital, Invus, Wellington Management, Nextech Invest, OrbiMed, Logos Capital, Woodline Partners LP, Casdin Capital | ||||
 | Cerapedics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $163.58M | Series G | 6/5/2024 | $15.23M | $744.31M | $5.64 | Undisclosed Investors | ||||
 | Genesis Molecular AI | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $340.28M | Series B-3 | 5/20/2026 | $40M | $806.79M | $9.33 | -- | ||||
 | Rivus Pharmaceuticals | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $224.04M | Series B-2 | 1/16/2025 | $122.98M | $506.82M | $4.76 | RA Capital Management, Bain Capital, BB Biotech AG, Longitutde Capital, Medicxi, RxCapital | ||||
 | Profluent | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $150M | Series B | 11/19/2025 | $106M | $502.78M | $34.07 | Altimeter Capital, Bezos Expeditions, Spark Capital, Insight Partners, Air Street Capital | ||||
 | RayzeBio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $795.51M | Series D | 9/13/2022 | $159.75M | $599.64M | $2.50 | Viking Global Investors, Sofinnova Investments, Wellington Management, Ally Bridge Group, Sands Capital, Laurion Capital Management, Soleus Capital | ||||
 | Seaport Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $330.1M | Series B | 10/21/2024 | $226M | $725.46M | $14.92 | General Atlantic, T. Rowe Price Associates, Foresite Capital, Invus, Goldman Sachs, CPP Investments, ARCH Venture Partners, Sofinnova Investments, Third Rock Ventures, PureTech Health | ||||
 | Avenzo Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $445.85M | Series B | 9/22/2025 | $60M | $616.96M | $2.22 | OrbiMed, SR One, Longwood Fund, Foresite Capital, Lilly Asia Ventures, Surveyor Capital, NEA, Deep Track Capital, Sofinnova Investments, Sands Capital, INCE Capital, TF Capital, Delos Capital, Quan Capital | ||||
 | Strand Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $266.03M | Series B-2 | 8/7/2025 | $120M | $567.33M | $10.88 | Kinnevik, Regeneron Ventures, ICONIQ Capital, Amgen Ventures, Alderline Group, JIC Venture Growth Investments, LG Technology Ventures, Gradiant, FPV Ventures, Playground Global, Eli Lilly, ANRI, Potentum Partners | ||||
 | Cellarity | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $435.63M | Series D | 12/23/2024 | $196.06M | $517.83M | $3.60 | Undisclosed Investors | ||||